David A. Six, PhD is a Principal Scientist at Venatorx Pharmaceuticals, where he supports the clinical-stage cefepime-taniborbactam combination and novel non-β-lactam inhibitors of penicillin-binding proteins.

Before joining Venatorx, David spent more than 8 years at Novartis, where he led antibacterial drug discovery programs and developed assays to measure bacterial compound accumulation. As part of this, he also led a team that developed a solid-phase extraction mass spectrometry assay to increase the efficiency of assays to measure bacterial compound accumulation. David has authored over 30 peer-reviewed publications and also owns a patent.

David received his masters and doctorate degrees from the University of California, San Diego, USA.